← All trials
NCT04591535
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2020
- Primary completion
- Mar 28, 2021
- Completion date
- Mar 28, 2021
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 8
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hong Kong WD Pharmaceutical Co., LimitedLead sponsor
- Lambda Therapeutic Research LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.